Reversal of residual neuromuscular block: Complications associated with perioperative management of muscle relaxation

British Journal of Anaesthesia

Volumn 119, Issue , 2017, Pages i53-i62

  Hunter, J M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

complications; neuromuscular blocking drugs; reversal

Indexed keywords

NEUROMUSCULAR BLOCKING AGENT;

ANESTHETIC RECOVERY; DELAYED EMERGENCE FROM ANESTHESIA; DRUG EFFECT; HUMAN; MUSCLE RELAXATION; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR MONITORING; PERIOPERATIVE PERIOD; PROCEDURES;

ANESTHESIA RECOVERY PERIOD; DELAYED EMERGENCE FROM ANESTHESIA; HUMANS; MUSCLE RELAXATION; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR MONITORING; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PERIOPERATIVE CARE;

EID: 85040063590     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aex318     Document Type: Conference Paper

References (77)

1. Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology 1942; 3: 418-20
2. Shafer SL. From d-Tubocurarine to sugammadex: The contributions of T Cecil Gray to modern anaesthetic practice. Br J Anaesth 2011; 107: 97-102
3. Gray TC, Halton J. A milestone in anaesthesia? (d-Tubocurarine Chloride). Proc R Soc Med 1946; 34: 400-8
4. Beecher HK, Todd DP. A study of the deaths associated with anesthesia and surgery. Ann Surg 1954; 140: 2-34
5. Utting JE. The era of relaxant anaesthesia. Br J Anaesth 1992; 69: 551-3
6. Payne JP, Hughes R, Al Azawi S. Neuromuscular blockade by neostigmine in anaesthetised man. Br J Anaesth 1980; 52: 69-76
7. Jones JE, Parker CJR, Hunter JM. Antagonism of blockade produced by atracurium or vecuronium with low doses of neostigmine. Br J Anaesth 1988; 61: 560-48
8. Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 2008; 100: 622-30
9. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007; 104: 555-62
10. Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: A comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009; 110: 1020-5
11. Sunaga H, Savarese JJ, McGilvra JD, et al. Preclinical pharmacology of CW002. Anesthesiology 2016; 125: 732-43
12. Baurain MJ, Dernovoi BS, DHollander AA, Hennart DA, Cantraine FR. Conditions to optimize the reversal action of neostigmine upon a vecuronium-induced neuromuscular block. Acta Anaesthesiol Scand 1996; 40: 574-8
13. Donati F. Residual paralysis: A real problem or did we invent a new disease? Can J Anesth 2013; 60: 714-29
14. Kopman AF, Eikermann M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia 2009; 64: S22-30
15. Khirwadkar R, Hunter JM. Neuromuscular physiology and pharmacology: An update. BJA CEACCP 2012; 12: 237-44
16. Ali HH, Utting JE, Gray TC. Stimulus frequency in the detection of neuromuscular block. Br J Anaesth 1970; 42: 967-78
17. Ali HH, Utting JE, Gray TC. Quantitative assessment of residual antidepolarising block (Part 1). Br J Anaesth 1971; 43: 473-7
18. Ali HH, Utting JE, Gray TC. Quantitative assessment of residual antidepolarising block (Part II). Br J Anaesth 1971; 43: 478-85
19. Engbaek J, Ostergaard D, Viby-Mogensen J. Double burst stimulation (DBS): A new pattern of nerve stimulation to identify residual neuromuscular block. Br J Anaesth 1989; 62: 274-8
20. Viby-Mogensen J, Jensen NH, Engbaek J, Ording H, Skovgaard LT, Chaemmer-Jorgensen B. Tactile and visual evaluation of the response to train-of-four nerve stimulation. Anesthesiology 1985; 63: 440-3
21. Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LT. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology 2000; 92: 977-84
22. Viby-Mogensen J. Postoperative residual curarization and evidence-based anaesthesia. Br J Anaesth 2000; 84: 301-3
23. Eriksson LI. Evidence-based practice and neuromuscular monitoring: its time for routine quantitative assessment. Anesthesiology 2003; 98: 1037-9
24. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarization: A meta-Analysis. Br J Anaesth 2007; 98: 302-16
25. Pedersen T, Viby-Mogensen J, Bang U, Olsen NV, Jensen E, Engbaek J. Does perioperative tactile evaluation of the trainof-four response influence the frequency of postoperative residual neuromuscular blockade? Anesthesiology 1990; 73: 835-9
26. Naguib M, Kopman AF, Lien CA, Hunter JM, Lopez A, Brull SJ. A survey of current management of neuromuscular block in the United States and Europe. Anesth Analg 2010; 111: 110-9
27. Butterly A, Bittner EA, George E, Sandberg WS, Eikermann M, Schmidt U. Postoperative residual curarization from intermediate-Acting neuromuscular blocking agents delays recovery room discharge. Br J Anaesth 2010; 105: 304-9
28. Debaene B, Plaud B, Dilly M-P, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003; 98: 1042-8
29. McCaul C, Tobin E, Boylan JF, McShane AJ. Atracurium is associated with postoperative residual curarization. Br J Anaesth 2002; 89: 766-9
30. Baillard C, Gehan G, Reboul-Marty J, Larmignat P, Samama CM, Cupa M. Residual curarization in the recovery room after vecuronium. Br J Anaesth 2000; 84: 394-5
31. Fortier L-P, McKeen D, Turner K, et al. A Canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade. Anesth Analg 2015; 121: 366-72
32. Harrison GG. Death attributable to anaesthesia: A 10-year survey (1967-1976). Br J Anaesth 1978; 50: 1041-6
33. Lunn JN, Hunter AR, Scott DB. Anaesthesia-related surgical mortality. Anaesthesia 1983; 38: 1090-6
34. Cooper ALO, Leigh JM, Tring IC. Admission on the intensive care unit after complications of anaesthetic techniques over 10 years. Anaesthesia 1989; 44: 953-8
35. Tiret L, Desmonts JM, Hatton F, Vourch G. Complications associated with anaesthesia: A prospective survey in France. Can J Anaesth 1986; 33: 336-44
36. Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41: 1095-103
37. Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. Br Med J 2012; 345: e6329
38. Sasaki N, Meyer MJ, Malviya SA, et al. Effects of neostigmine reversal of nondepolarizing neuromuscular blocking agents on postoperative respiratory outcomes. Anesthesiology 2014; 121: 959-68
39. McLean DJ, Diaz-Gil D, Farhan HN, Ladha KS, Kurth T, Eikermann M. Dose-dependent association between intermediate-Acting neuromuscular-blocking agents and postoperative respiratory complications. Anesthesiology 2015; 122: 1201-13
40. Bulka CM, Terekhov MA, Martin BJ, Dmochowski RR, Hayes RM, Ehrenfeld JM. Nondepolarizing neuromuscular blocking agents, reversal, and risk of postoperative pneumonia. Anesthesiology 2016; 125: 647-55
41. Bronsert MR, Henderson WG, Monk TG, et al. Intermediateacting nondepolarizing neuromuscular blocking agents and risk of postoperative 30-day morbidity and mortality, and long-Term survival. Anesth Analg 2017; 124: 1476-83
42. Murphy GS, Szokol JW, Avram MJ, et al. Residual neuromuscular block in the elderly: incidence and clinical implications. Anesthesiology 2015; 123: 1322-36
43. Miskovic A, Lumb AB. Postoperative pulmonary complications. Br J Anaesth 2017; 118: 317-34
44. Arbous MS, Meursing AE, van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005; 102: 257-68
45. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 107: 130-7
46. Hunter JM. Antagonising neuromuscular block at the end of surgery. To reverse or not to reverse? That is the question. Br Med J 2012; 345: e6666
47. Fagerlund MJ, Fink H, Baumuller E, et al. Postanaesthesia pulmonary complications after use of muscle relaxants in Europe: study protocol of the POPULAR study. Eur J Anaesthesiol 2016; 33: 381-3
48. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth 2009; 103: 115-29
49. Bevan DR, Kahwaji R, Ansermino JM, et al. Residual block after mivacurium with or without edrophonium reversal in adults and children. Anesthesiology 1996; 84: 362-7
50. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41: 266-70
51. Duvaldestin P, Kuizenga K, Saldien V, et al. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium-or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010; 110: 74-82
52. DeCoopman M, Cammu G, Suy K, Heeringa M, Demeyer I. Reversal of pancuronium induced block by the selective relaxant binding agent sugammadex: 9AP 2-1. Eur J Anaesthesiol 2007; 24: S110
53. Tassonyi E, Pongracz A, Nemes R, Asztalos L, Lengyel S, Fulesdi B. Reversal of pipecuronium-induced moderate neuromuscular block with sugammadex in the presence of a sevoflurane anesthetic: A randomized trial. Anesth Analg 2015; 121: 373-80
54. Staals LM, Snoeck MMJ, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: A pharmacokinetic study. Br J Anaesth 2010; 104: 31-9
55. Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth 2014; 112: 498-505
56. Baete S, Vercruysse G, Vander Laenen M, et al. The effect of deep versus moderate neuromuscular block on surgical conditions and postoperative respiratory function in bariatric laparoscopic surgery: A randomized, double blind clinical trial. Anesth Analg 2017; 124: 1469-75
57. Bruintjes MH, van Helden EV, Braat AE, et al. Deep neuromuscular block to optimize surgical space conditions during laparoscopic surgery: A systematic review and meta-Analysis. Br J Anaesth 2017; 118: 834-42
58. Tobias JD. Current evidence for the use of sugammadex in children. Paediatr Anesth 2017; 27: 118-25
59. Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: A randomized, controlled study. Br J Anaesth 2015; 115: 743-51
60. Cammu GV, Smet V, De Jongh K, Vandeput D. A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery. Anaesth Intensive Care 2012; 40: 999-1006
61. Gaszynski T, Szewczyk T, Gaszynski W. Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia. Br J Anaesth 2012; 108: 236-9
62. Kotake Y, Ochiai R, Suzuki T, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg 2013; 117: 345-51
63. Ledowski T, Falke L, Johnston F, et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade. Eur J Anaesthesiol 2014; 31: 423-9
64. Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology 2010; 113: 1054-60
65. Kaufhold N, Schaller SJ, Stauble CG, et al. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2. Br J Anaesth 2016; 116: 233-40
66. Baumuller E, Schaller SJ, Chiquito Lama Y, et al. Postoperative impairment of motor function at train-of-four ratio 0.9 cannot be improved by sugammadex (1mg kg1). Br J Anaesth 2015; 114: 785-93.
67. Eleveld DJ, Kuizenga K, Proost JH, Wierda JMKH. A temporary decrease in twitch response during reversal of rocuroniuminduced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007; 104: 582-4
68. Zwiers A, van den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex. Clin Drug Investig 2011; 31: 101-11
69. Keating GM. Sugammadex: A review of neuromuscular blockade reversal. Drugs 2016; 76: 1041-52
70. Eikermann M, Zaremba S, Malhotra A, Jordan AS, Rosow C, Chamberlin NL. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth 2008; 101: 344-9
71. Godai K, Hasegawa-Moriyama M, Kuniyoshi T, et al. Three cases of suspected sugammadex-induced hypersensitivity reactions. Br J Anaesth 2012; 109: 216-8
72. McDonnell NJ, Pavy TJG, Green LK, Platt PR. Sugammadex in the management of rocuronium-induced anaphylaxis. Br J Anaesth 2011; 106: 199-201
73. Heerdt PM, Sunaga H, Owen JS, et al. Dose-response and cardiopulmonary side effects of the novel neuromuscularblocking drug CW002 in man. Anesthesiology 2016; 125: 1136-43
74. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, et al. Calabadion: A new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents. Anesthesiology 2013; 119: 317-25
75. Haerter F, Simons JC, Foerster U, et al. Comparative effectiveness of calabadion and sugammadex to reverse nondepolarizing neuromuscular-blocking agents. Anesthesiology 2015; 123: 1337-49
76. Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth Analg 2010; 111: 129-40
77. Naguib M, Dexter F, Brull SJ. Neuromuscular monitoring as the art of probability. Anesth Analg 2017; 124: 1400-2